{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:35:24Z","timestamp":1792017324684,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003382","name":"MEXT | JST | Core Research for Evolutional Science and Technology","doi-asserted-by":"publisher","award":["JPMJCR2011"],"award-info":[{"award-number":["JPMJCR2011"]}],"id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ama121029j0001"],"award-info":[{"award-number":["JP22ama121029j0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["18H04989, 19H04821"],"award-info":[{"award-number":["18H04989, 19H04821"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04038, 17K08622, 20K07332, 20H03441"],"award-info":[{"award-number":["17H04038, 17K08622, 20K07332, 20H03441"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sphingosine 1-phosphate receptor 1 (S1PR1), a G protein-coupled receptor, is required for lymphocyte trafficking, and is a promising therapeutic target in inflammatory diseases. Here, we synthesize a competitive S1PR1 antagonist, KSI-6666, that effectively suppresses pathogenic inflammation. Metadynamics simulations suggest that the interaction of KSI-6666 with a methionine residue Met124 in the ligand-binding pocket of S1PR1 may inhibit the dissociation of KSI-6666 from S1PR1. Consistently, in vitro functional and mutational analyses reveal that KSI-6666 causes pseudoirreversible inhibition of S1PR1, dependent on the Met124 of the protein and substituents on the distal benzene ring of KSI-6666. Moreover, in vivo study suggests that this pseudoirreversible inhibition is responsible for the persistent activity of KSI-6666.<\/jats:p>","DOI":"10.1038\/s41467-024-49893-8","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:01:44Z","timestamp":1721383304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pseudoirreversible inhibition elicits persistent efficacy of a sphingosine\u00a01-phosphate receptor\u00a01 antagonist"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuya","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ohsawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morimichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Okuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0686-9444","authenticated-orcid":false,"given":"Wataru","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kano","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naho","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-1014","authenticated-orcid":false,"given":"Kenta","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1085-5996","authenticated-orcid":false,"given":"Nobuko","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatsugu","family":"Hirokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0341-6154","authenticated-orcid":false,"given":"Taishin","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"49893_CR1","doi-asserted-by":"crossref","unstructured":"Cartier, A. & Hla, T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science 366, eaar5551 (2019).","DOI":"10.1126\/science.aar5551"},{"key":"49893_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010818-021358","volume":"59","author":"J Chun","year":"2019","unstructured":"Chun, J., Kihara, Y., Jonnalagadda, D. & Blaho, V. A. Fingolimod: lessons learned and new opportunities for treating multiple sclerosis and other disorders. Annu. Rev. Pharmacol. Toxicol. 59, 149\u2013170 (2019).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"49893_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883\u2013897 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"49893_CR4","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.phrs.2020.104793","volume":"156","author":"E Jozefczuk","year":"2020","unstructured":"Jozefczuk, E., Guzik, T. J. & Siedlinski, M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol. Res. 156, 104793 (2020).","journal-title":"Pharmacol. Res."},{"key":"49893_CR5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","volume":"168","author":"J Camm","year":"2014","unstructured":"Camm, J., Hla, T., Bakshi, R. & Brinkmann, V. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am. Heart J. 168, 632\u2013644 (2014).","journal-title":"Am. Heart J."},{"key":"49893_CR6","doi-asserted-by":"publisher","first-page":"e52985","DOI":"10.1371\/journal.pone.0052985","volume":"7","author":"RM Fryer","year":"2012","unstructured":"Fryer, R. M. et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P(1)) and hypertension (S1P(3)) in rat. PLoS ONE 7, e52985 (2012).","journal-title":"PLoS ONE"},{"key":"49893_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nchembio804","volume":"2","author":"MG Sanna","year":"2006","unstructured":"Sanna, M. G. et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2, 434\u2013441 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"49893_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.intimp.2011.07.004","volume":"11","author":"G Tarrason","year":"2011","unstructured":"Tarrason, G. et al. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int. Immunopharmacol. 11, 1773\u20131779 (2011).","journal-title":"Int. Immunopharmacol."},{"key":"49893_CR9","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/j.bmcl.2018.10.042","volume":"28","author":"A Marciniak","year":"2018","unstructured":"Marciniak, A., Camp, S. M., Garcia, J. G. N. & Polt, R. An update on sphingosine-1-phosphate receptor 1 modulators. Bioorg. Med. Chem. Lett. 28, 3585\u20133591 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"49893_CR10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.chembiol.2012.07.016","volume":"19","author":"J Quancard","year":"2012","unstructured":"Quancard, J. et al. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem. Biol. 19, 1142\u20131151 (2012).","journal-title":"Chem. Biol."},{"key":"49893_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nrd2082","volume":"5","author":"RA Copeland","year":"2006","unstructured":"Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730\u2013739 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"49893_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrd.2015.18","volume":"15","author":"RA Copeland","year":"2016","unstructured":"Copeland, R. A. The drug-target residence time model: a 10-year retrospective. Nat. Rev. Drug Discov. 15, 87\u201395 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"49893_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.coph.2016.07.004","volume":"30","author":"CS Tautermann","year":"2016","unstructured":"Tautermann, C. S. Impact, determination and prediction of drug-receptor residence times for GPCRs. Curr. Opin. Pharmacol. 30, 22\u201326 (2016).","journal-title":"Curr. Opin. Pharmacol."},{"key":"49893_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1039\/C6MD00581K","volume":"8","author":"M Bernetti","year":"2017","unstructured":"Bernetti, M., Cavalli, A. & Mollica, L. Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling. Medchemcomm 8, 534\u2013550 (2017).","journal-title":"Medchemcomm"},{"key":"49893_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00716-z","volume":"8","author":"DA Sykes","year":"2017","unstructured":"Sykes, D. A. et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat. Commun. 8, 763 (2017).","journal-title":"Nat. Commun."},{"key":"49893_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1124\/mol.115.101832","volume":"89","author":"DA Sykes","year":"2016","unstructured":"Sykes, D. A. et al. Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy. Mol. Pharmacol. 89, 593\u2013605 (2016).","journal-title":"Mol. Pharmacol."},{"key":"49893_CR17","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1021\/acschemneuro.0c00477","volume":"11","author":"R Agren","year":"2020","unstructured":"Agren, R. et al. Ligand with two modes of interaction with the dopamine D2 receptor\u2014an induced-fit mechanism of insurmountable antagonism. ACS Chem. Neurosci. 11, 3130\u20133143 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"49893_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1046\/j.1472-8206.2002.00095.x","volume":"16","author":"G Vauquelin","year":"2002","unstructured":"Vauquelin, G., Van Liefde, I., Birzbier, B. B. & Vanderheyden, P. M. New insights in insurmountable antagonism. Fundam. Clin. Pharmacol. 16, 263\u2013272 (2002).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"49893_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0165-6147(00)01523-6","volume":"21","author":"MJ Lew","year":"2000","unstructured":"Lew, M. J., Ziogas, J. & Christopoulos, A. Dynamic mechanisms of non-classical antagonism by competitive AT(1) receptor antagonists. Trends Pharmacol. Sci. 21, 376\u2013381 (2000).","journal-title":"Trends Pharmacol. Sci."},{"key":"49893_CR20","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1021\/jm980299k","volume":"41","author":"JJ Hale","year":"1998","unstructured":"Hale, J. J. et al. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. 41, 4607\u20134614 (1998).","journal-title":"J. Med. Chem."},{"key":"49893_CR21","doi-asserted-by":"publisher","first-page":"E386","DOI":"10.1073\/pnas.1424461112","volume":"112","author":"P Tiwary","year":"2015","unstructured":"Tiwary, P., Limongelli, V., Salvalaglio, M. & Parrinello, M. Kinetics of protein-ligand unbinding: predicting pathways, rates, and rate-limiting steps. Proc. Natl Acad. Sci. USA 112, E386\u2013E391 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"49893_CR22","doi-asserted-by":"publisher","first-page":"10184","DOI":"10.1073\/pnas.1103547108","volume":"108","author":"I Buch","year":"2011","unstructured":"Buch, I., Giorgino, T. & De Fabritiis, G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc. Natl Acad. Sci. USA 108, 10184\u201310189 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"49893_CR23","doi-asserted-by":"publisher","first-page":"e1700014","DOI":"10.1126\/sciadv.1700014","volume":"3","author":"P Tiwary","year":"2017","unstructured":"Tiwary, P., Mondal, J. & Berne, B. J. How and when does an anticancer drug leave its binding site? Sci. Adv. 3, e1700014 (2017).","journal-title":"Sci. Adv."},{"key":"49893_CR24","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1021\/acs.jctc.8b00230","volume":"14","author":"DB Kokh","year":"2018","unstructured":"Kokh, D. B. et al. Estimation of drug-target residence times by tau-random acceleration molecular dynamics simulations. J. Chem. Theory Comput. 14, 3859\u20133869 (2018).","journal-title":"J. Chem. Theory Comput."},{"key":"49893_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1021\/ar500356n","volume":"48","author":"A Cavalli","year":"2015","unstructured":"Cavalli, A., Spitaleri, A., Saladino, G. & Gervasio, F. L. Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms. Acc. Chem. Res. 48, 277\u2013285 (2015).","journal-title":"Acc. Chem. Res."},{"key":"49893_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1021\/acs.jcim.6b00679","volume":"57","author":"D Callegari","year":"2017","unstructured":"Callegari, D. et al. Metadynamics simulations distinguish short- and long-residence-time inhibitors of cyclin-dependent kinase 8. J. Chem. Inf. Model 57, 159\u2013169 (2017).","journal-title":"J. Chem. Inf. Model"},{"key":"49893_CR27","doi-asserted-by":"publisher","first-page":"12788","DOI":"10.1021\/acs.chemrev.0c00534","volume":"120","author":"S Decherchi","year":"2020","unstructured":"Decherchi, S. & Cavalli, A. Thermodynamics and kinetics of drug-target binding by molecular simulation. Chem. Rev. 120, 12788\u201312833 (2020).","journal-title":"Chem. Rev."},{"key":"49893_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sbi.2017.10.010","volume":"48","author":"P Sledz","year":"2018","unstructured":"Sledz, P. & Caflisch, A. Protein structure-based drug design: from docking to molecular dynamics. Curr. Opin. Struct. Biol. 48, 93\u2013102 (2018).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"49893_CR29","doi-asserted-by":"publisher","first-page":"12562","DOI":"10.1073\/pnas.202427399","volume":"99","author":"A Laio","year":"2002","unstructured":"Laio, A. & Parrinello, M. Escaping free-energy minima. Proc. Natl Acad. Sci. USA 99, 12562\u201312566 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"49893_CR30","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1021\/jm201533b","volume":"55","author":"MA Ibrahim","year":"2012","unstructured":"Ibrahim, M. A. et al. Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists. J. Med. Chem. 55, 1368\u20131381 (2012).","journal-title":"J. Med. Chem."},{"key":"49893_CR31","doi-asserted-by":"crossref","unstructured":"Stewart, G. D., Sexton, P. M. & Christopoulos, Inverse Agonists: Encyclopedia of Psychopharmacology (ed. Stolerman, I. P.) (Springer, Berlin, Heidelberg, 2015).","DOI":"10.1007\/978-3-642-36172-2_297"},{"key":"49893_CR32","doi-asserted-by":"publisher","first-page":"e74285","DOI":"10.1371\/journal.pone.0074285","volume":"8","author":"M Rey","year":"2013","unstructured":"Rey, M. et al. Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator. PLoS ONE 8, e74285 (2013).","journal-title":"PLoS ONE"},{"key":"49893_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1161\/01.CIR.0000152101.41037.AB","volume":"111","author":"H Shimizu","year":"2005","unstructured":"Shimizu, H. et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111, 222\u2013229 (2005).","journal-title":"Circulation"},{"key":"49893_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-3083.2009.02243.x","volume":"69","author":"D Brudzewsky","year":"2009","unstructured":"Brudzewsky, D. et al. Genome-wide gene expression profiling of SCID mice with T-cell-mediated Colitis. Scand. J. Immunol. 69, 437\u2013446 (2009).","journal-title":"Scand. J. Immunol."},{"key":"49893_CR35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1126\/science.1215904","volume":"335","author":"MA Hanson","year":"2012","unstructured":"Hanson, M. A. et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851\u2013855 (2012).","journal-title":"Science"},{"key":"49893_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41589-021-00930-3","volume":"18","author":"Z Xu","year":"2022","unstructured":"Xu, Z. et al. Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism. Nat. Chem. Biol. 18, 281\u2013288 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"49893_CR37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/med.21307","volume":"34","author":"D Guo","year":"2014","unstructured":"Guo, D., Hillger, J. M., IJzerman, A. P. & Heitman, L. H. Drug-target residence time-a case for G protein-coupled receptors. Med. Res. Rev. 34, 856\u2013892 (2014).","journal-title":"Med. Res. Rev."},{"key":"49893_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.drudis.2013.02.010","volume":"18","author":"G Dahl","year":"2013","unstructured":"Dahl, G. & Akerud, T. Pharmacokinetics and the drug-target residence time concept. Drug Discov. Today 18, 697\u2013707 (2013).","journal-title":"Drug Discov. Today"},{"key":"49893_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cbpa.2010.06.176","volume":"14","author":"H Lu","year":"2010","unstructured":"Lu, H. & Tonge, P. J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467\u2013474 (2010).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"49893_CR40","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1111\/j.1476-5381.2012.01897.x","volume":"166","author":"D Guo","year":"2012","unstructured":"Guo, D., Mulder-Krieger, T., IJzerman, A. P. & Heitman, L. H. Functional efficacy of adenosine A(2)A receptor agonists is positively correlated to their receptor residence time. Br. J. Pharmacol. 166, 1846\u20131859 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"49893_CR41","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.1073\/pnas.1305378110","volume":"110","author":"EV Schneider","year":"2013","unstructured":"Schneider, E. V., Bottcher, J., Huber, R., Maskos, K. & Neumann, L. Structure-kinetic relationship study of CDK8\/CycC specific compounds. Proc. Natl Acad. Sci. USA 110, 8081\u20138086 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"49893_CR42","doi-asserted-by":"publisher","unstructured":"Knockenhauer, K. E. & Copeland, R. A. The importance of binding kinetics and drug-target residence time in pharmacology. Br. J. Pharmacol. https:\/\/doi.org\/10.1111\/bph.16104. (2023). Online ahead of print.","DOI":"10.1111\/bph.16104"},{"key":"49893_CR43","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1074\/jbc.M609648200","volume":"282","author":"Y Fujiwara","year":"2007","unstructured":"Fujiwara, Y. et al. Identification of the hydrophobic ligand binding pocket of the S1P1 receptor. J. Biol. Chem. 282, 2374\u20132385 (2007).","journal-title":"J. Biol. Chem."},{"key":"49893_CR44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen, J. A. et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 18, 1021\u20131033 (2019).","journal-title":"Lancet Neurol."},{"key":"49893_CR45","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"JQ Tran","year":"2017","unstructured":"Tran, J. Q. et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J. Clin. Pharmacol. 57, 988\u2013996 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"49893_CR46","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn, W. J. et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 385, 1280\u20131291 (2021).","journal-title":"N. Engl. J. Med."},{"key":"49893_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn, W. J. et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology 158, 550\u2013561 (2020).","journal-title":"Gastroenterology"},{"key":"49893_CR48","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1021\/acs.jctc.3c00660","volume":"19","author":"D Ray","year":"2023","unstructured":"Ray, D. & Parrinello, M. Kinetics from metadynamics: principles, applications, and outlook. J. Chem. Theory Comput. 19, 5649\u20135670 (2023).","journal-title":"J. Chem. Theory Comput."},{"key":"49893_CR49","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1038\/s41596-020-0342-4","volume":"15","author":"S Raniolo","year":"2020","unstructured":"Raniolo, S. & Limongelli, V. Ligand binding free-energy calculations with funnel metadynamics. Nat. Protoc. 15, 2837\u20132866 (2020).","journal-title":"Nat. Protoc."},{"key":"49893_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/jpet.118.254268","volume":"369","author":"H Al-Shamma","year":"2019","unstructured":"Al-Shamma, H. et al. The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis. J. Pharmacol. Exp. Ther. 369, 311\u2013317 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"49893_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"49893_CR52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/jm050540c","volume":"49","author":"W Sherman","year":"2006","unstructured":"Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A. & Farid, R. Novel procedure for modeling ligand\/receptor induced fit effects. J. Med. Chem. 49, 534\u2013553 (2006).","journal-title":"J. Med. Chem."},{"key":"49893_CR53","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1021\/acs.jctc.8b01026","volume":"15","author":"K Roos","year":"2019","unstructured":"Roos, K. et al. OPLS3e: extending force field coverage for drug-like small molecules. J. Chem. Theory Comput. 15, 1863\u20131874 (2019).","journal-title":"J. Chem. Theory Comput."},{"key":"49893_CR54","doi-asserted-by":"crossref","unstructured":"Kurki, M., Poso, A., Bartos, P. & Miettinen, M. S. Structure of POPC lipid bilayers in OPLS3e force field. J. Chem. Inf. Model 62, 6462\u20136474 (2022).","DOI":"10.1021\/acs.jcim.2c00395"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49893-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:01:56Z","timestamp":1721383316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-49893-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["49893"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-49893-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YM, Y. Ohsawa, TS, YY, KO, HI, AY, MH, and Y. Okuhara are employees of Kissei Pharmaceutical Co., Ltd. and may hold stock in the company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5743"}}